Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.
about
IL-2-controlled expression of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy mice: implication to multiorgan inflammation and control of skin and lung inflammationN-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.Therapeutic potential of CCR1 antagonists for multiple myeloma.Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.
P2860
Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Evaluation of the effect of th ...... l challenge in human subjects.
@en
Evaluation of the effect of th ...... l challenge in human subjects.
@nl
type
label
Evaluation of the effect of th ...... l challenge in human subjects.
@en
Evaluation of the effect of th ...... l challenge in human subjects.
@nl
prefLabel
Evaluation of the effect of th ...... l challenge in human subjects.
@en
Evaluation of the effect of th ...... l challenge in human subjects.
@nl
P2093
P2860
P1433
P1476
Evaluation of the effect of th ...... el challenge in human subjects
@en
P2093
Alan Clucas
Cunshan Wang
Jeanett Borregaard
Jesper Sonne
Lisa A Beck
Naitee Ting
P2860
P304
P356
10.1111/J.1600-0536.2008.01365.X
P50
P577
2008-10-01T00:00:00Z